Company: HROW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001641172-25-000925
Chunk: 7

Company: HARROW, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 1
Chunk 7
---
 recorded
a loss of $3,171,000 related to the sale of our investment in Eton.

Sales and Marketing

The focus of our sales and marketing
is in the U.S. We do, however, believe that our drug candidates and drug products could have commercial appeal in international markets,
and have engaged distributors and entered into out-licensing arrangements for certain of our products and proprietary formulations in
certain non-U.S. markets, including Canada. Our sales and marketing activities consist primarily of efforts to educate doctors, ambulatory
surgery centers, healthcare systems, hospitals and other users throughout the U.S. about our drug products. We expect that we may experience
growth in the sales of our products in future periods, particularly in light of our recent product launches and commercial campaigns.
However, we may not be successful in doing so, whether due to the size of the markets for such products, which could be smaller than
we expect, the timing of market entry relative to competitive products, the availability of alternative compounded formulations or FDA-approved
drugs, the price of our products relative to alternative products or the success of our sales and marketing efforts, which is dependent
on our ability to further build and continue to grow a qualified and adequate internal sales function.

We expect
to continue to acquire and/or develop additional FDA-approved ophthalmic products that allow us to leverage our existing commercial infrastructure
to promote, sell, and ultimately bring these products to market. As we execute this strategy, we will continue to expand our sales and
marketing team, expertise and expenses.

Supply Chains

100%
of our ImprimisRx finished compounded products are made in the U.S. at our compounding facilities located in New Jersey.

We do
not manufacture any of our branded pharmaceutical products and rely on third party manufacturing partners to make these finished goods.
The following table describes by product the country where our finished branded products are made:

    Product
     
    Country Finished Product Is Manufactured
  
    IHEEZO
     
    France
  
    VEVYE
     
    U.S.
  
    TRIESENCE
     
    U.S.
  
    VIGAMOX
     
    Belgium
  
    ILVERO
     
    Belgium
  
    FLAREX
     
    U.S.
  
    NATACYN
     
    U.S.
  
    TOBRADEX ST
     
    U.S.
  
    ZERVIATE
     
    France
  
    VERK